Evidence map›Paper›PMID 39105797›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Interaction between resveratrol and SIRT1: role in neurodegenerative diseases.

Lin Zhu, Miaomiao Yang, Lehao Fan, Qiuying Yan, Lifeng Zhang, Ping Mu, Fangjin Lu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lin ZhuDepartment of Biochemistry and Molecular Biology, Shenyang Medical College, Shenyang, 113004, People's Republic of China.
Miaomiao YangDepartment of Biochemistry and Molecular Biology, Shenyang Medical College, Shenyang, 113004, People's Republic of China.
Lehao FanBasic Medical College, Shenyang Medical College, Shenyang, 113004, People's Republic of China.
Qiuying YanBasic Medical College, Shenyang Medical College, Shenyang, 113004, People's Republic of China.
Lifeng ZhangDepartment of Public Health, Shenyang Medical College, Shenyang, 113004, People's Republic of China. zgykdxzlf@163.com.
Ping MuKey Laboratory of Human Ethnic Specificity and Phenomics of Critical Illness in Liaoning Province, Shenyang Medical College, Shenyang, 113004, People's Republic of China. pingmu@symc.edu.cn.
Fangjin LuDepartment of Pharmaceutical Analysis, Shenyang Medical College, Shenyang, 113004, People's Republic of China. lufangjin@symc.edu.cn.

Funding

Foundation of Chunhui Program-Cooperative Research Project of the Ministry of Education 202200846Foundation of the Education Department of Liaoning Province of China Foundation of the Education Department of Liaoning Province of ChinaLiaoning Provincial Natural Science Foundation of China 2022-NLTS-14-04
6 · The paper itself

Abstract

Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, pose significant health challenges and economic burdens worldwide. Recent studies have emphasized the potential therapeutic value of activating silent information regulator-1 (SIRT1) in treating these conditions. Resveratrol, a compound known for its ability to potently activate SIRT1, has demonstrated promising neuroprotective effects by targeting the underlying mechanisms of neurodegeneration. In this review, we delve into the crucial role of resveratrol-mediated SIRT1 upregulation in improving neurodegenerative diseases. The role of the activation of SIRT1 by resveratrol was reviewed. Moreover, network pharmacology was used to elucidate the possible mechanisms of resveratrol in these diseases. Activation of SIRT1 by resveratrol had positive effects on neuronal function and survival and alleviated the hallmark features of these diseases, such as protein aggregation, oxidative stress, neuroinflammation, and mitochondrial dysfunction. In terms of network pharmacology, the signaling pathways by which resveratrol protects against different neurodegenerative diseases were slightly different. Although the precise mechanisms underlying the neuroprotective effects of resveratrol and SIRT1 activation remain under investigation, these findings offer valuable insights into potential therapeutic strategies for neurodegenerative diseases.

Indexed as

Neurodegenerative DiseasesNeuroprotective AgentsResveratrolSirtuin 1AnimalsHumansNeuroprotective AgentsResveratrolSIRT1 protein, humanSirtuin 1Alzheimer’s diseaseHuntington’s diseaseParkinson’s diseaseResveratrolSIRT1

Identifiers

PMID39105797

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.